DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment



Molecular Imaging Homepage

New PET imaging agent predicts tumor response to lung cancer drug Could lead to better patient management and outcomes

PET beats SPECT for detecting coronary artery disease: study Detected 79 percent of severe obstructive cases versus 70 percent

PET/MR and the future of pediatric chemotherapy Dr. Ashok Joseph Theruvath, postdoctoral research fellow in the Molecular Imaging Program at the Stanford School of Medicine discusses promising research for assessing pediatric chemo outcomes

Availity announces debut of pre-clearance service at HIMSS Confirms imaging authorization in minutes and ensures patient payments prior to visit

NTP Radioisotopes facility resumes production following hydrogen leak Produces Mo-99 for US, European and other global customers

NCCN adds Axumin to guidelines for prostate cancer treatment Enhances support for imaging agent from private payors

Lisa Hazen ARRT appoints new Nuclear Medicine Technology (NMT) Relationship Manager

SHINE completes Building One of medical isotope production facility Facility is projected to become domestic source for Mo-99 production in US

Ian Wilson ImaginAb appoints chief operating officer

Study finds patients lack info about imaging exams Researchers uncover what they want to know

Transaxial 11C-sarcosine hybrid PET/CT
of the anterior right prostate gland

Courtesy of the University of Michigan

New PET tracer for prostate cancer shows benefits over current standard: study

by Lauren Dubinsky , Senior Reporter
A study recently published in The Journal of Nuclear Medicine may have found a better PET tracer for imaging prostate cancer.

Researchers at the University of Michigan compared the effectiveness of the current standard, 11C-choline, to Carbon-11 labeled sarcosine (11C-sarcosine).

Story Continues Below Advertisement

The (#1 Resource) for Medical Imaging and Peripherals. Call 1-949-273-8000

As a Master Distributor for major brands Barco, Philips, and Sony, we offer custom imaging solutions. With our renowned OEM Solutions and Service/Repair Center, Ampronix is a one-stop shop for HD Medical LCD Displays--Printers--Recorders--4K Cameras

Dr. Morand Piert, professor of radiology at the university, explained that 11C-sarcosine was considered for prostate cancer imaging because metabolomic data indicated strongly elevated tissue levels in localized prostate cancer, and particularly in metastatic disease.

Preclinical experiments involving mice revealed that tumor-to-background ratios obtained from 11C-sarcosine PET were much higher than those obtained with 11C-choline. They then performed the first 11C-sarcosine PET/CT scan on a human with prostate cancer and found it can generate high-contrast images.

The researchers concluded that 11C-sarcosine is a viable PET tracer for imaging prostate cancer and has potential benefits over 11C-choline.

Aside from skin cancer, prostate cancer is the most prevalent cancer among men in the U.S. The American Cancer Society estimates that there will be about 161,360 new cases of prostate cancer in 2017.

Sarcosine plays a vital role in the aggressiveness and progression of the disease. It's an excellent imaging target because it enters cells through proton-coupled amino acid transporters (PAT), which are overexpressed in solid tumors.

11C-sarcosine could also be used for identifying and characterizing other types of cancer. According to the researchers, that's because it's the first tracer that can interrogate the activity of PATs.

In the brain, PATs are involved in the neuronal amino acid transport process and in the intestinal tract, certain PATs act as nutrients and drug transporters.

The researchers also noted that PAT function has been connected to the amino acid-sensing engine that drives the activation of an important target for anti-cancer drugs. They believe that elevated 11C-sarcosine may be potentially useful for monitoring cancer treatments, but more research is needed to confirm that.

"The tracer could be useful for malignancies with elevated PAT expression," said Piert. "However, since the PAT expression is unknown for most malignancies, we honestly don't know the answer to the question."

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.